16:30 EST AbbVie to acquire Cerevel Therapeutics for $45.00 per share in cash
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie and BigHat Biosciences enter therapeutic research collaboration
- ImmunoGen downgraded to Neutral from Overweight at Piper Sandler
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Hold from Buy at Deutsche Bank
- ImmunoGen downgraded to Hold from Buy at Truist